Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
Dow
AstraZeneca
McKesson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

SOLIRIS Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: SOLIRIS
Pharmacology for SOLIRIS
Mechanism of ActionComplement Inhibitors

US Patents for SOLIRIS

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Ra Pharmaceuticals, Inc. (Cambridge, MA) 2035-06-12 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2031-03-08 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX Orphan search
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2034-10-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for SOLIRIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
10C0016 France   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
C00758904/01 Switzerland   Start Trial FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
SPC/GB10/015 United Kingdom   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTERED: UK EU/1/07/393/001 20070620
SPC002/2010 Ireland   Start Trial SPC002/2010: 20100902, EXPIRES: 20200430
C300433 Netherlands   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Boehringer Ingelheim
Moodys
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.